International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7844467
Original Article
Comparison of Positivity Rates of COVID-19 Rapid Antigen Tests (RAT) and GeneXpert During COVID-19 Pandemic in a Tertiary Care Hospital, Mumbai, Maharashtra
 ,
 ,
 ,
 ,
 ,
 ,
Published
April 19, 2023
Abstract
The advent of the coronavirus disease 2019 (COVID-19) in India caused a new range of challenges in diagnosing the virus & containing its community spread. Various point-of-care tests have been introduced for rapid diagnosis. Although rapid antigen tests (RAT) are the most commonly used, the false-negative rates are high. The purpose of this study was to compare the positivity rate of a molecular diagnostic test such as GeneXpert in RAT negative cases of COVID-19 during COVID pandemic. A retrospective observational analysis conducted on a total of 13633 symptomatic patients’ samples were tested for RAT & GeneXpert of which 1508 were positive (11.06%). Out of 20526 symptomatic patients tested for GeneXpert, 3811 were positive (18.56%) and out of 12125 RAT negatives, 214 patients tested GeneXpert positive (1.8%). The main conclusions of this study were that negative rapid antigen tests should always be confirmed with a molecular diagnostic test such as GeneXpert or RT-PCR for the diagnosis of COVID-19 in symptomatic patients. Proper methods of sample collection must be ensured as improper methods might lead to increase in the number of false-negative results on point-of-care &; screening tests.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
2332 Views
24 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved